Lexicon Cuts Commercial Operation, Focuses On R&D After FDA Letdown
Pipeline Includes Neuropathic Pain, Cardiomyopathy, Obesity
With a US FDA determination that sotagliflozin cannot be approved for type 1 diabetes at this time, Lexicon is shutting down its commercial organization to focus on its R&D pipeline.
